Presentation of Obefazimod for Ulcerative Colitis and Colon Cancer at DDW 2024

Abivax recently announced the presentation of four studies on its drug obefazimod at Digestive Disease Week 2024 in Washington, D.C. These studies focus on the use of this drug in cases of ulcerative colitis and in a preclinical model of colon cancer associated with inflammation. The congress will take place from May 18 to 21, 2024.

Sheldon Sloan, Chief Medical Officer of Abivax, expressed his enthusiasm for the presentation of these abstracts, highlighting the novel mechanism of action of obefazimod which is showing promising results in reducing the number of tumors in mouse models of cancer. The event will allow for in-depth discussions with experts in the field of inflammatory bowel diseases (IBD).

Results from various clinical trials will be presented, including showing the effectiveness and safety of obefazimod over periods of up to 96 weeks. Another aspect of the presentation will include the drug's impacts on key protein interactions in RNA biogenesis.